Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare, outlines how cytochrome P450 enzymes can impact medication efficacy in patients taking multiple drugs.
When medications are metabolized by the same enzymes, you run the risk of drug-drug interactions, said Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare.
Transcript
Can you explain the role of cytochrome P450 enzymes in adverse drug events and other outcomes?
So the cytochrome P450 (CYP450) family of enzymes are essential for the metabolism of many medications. And today about 80% to 90% of commonly prescribed medications are actually metabolized by this class of enzymes. And when you have so many medications that are metabolized by the same enzymes, you really run the risk of competition or drug-drug interactions that could occur at that metabolic pathway. And so if you have multiple medications competing for metabolism on any given enzyme, you really can ultimately impact the effectiveness of that medication or even the safety of that medication.
What different pharmaceutical classes are affected by this enzyme? Are some more impacted than others?
There's a lot of medications and medication drug classes that are affected by this family of enzymes. You have statins, beta blockers, a big one is antidepressants. And then also, grapefruit juice can impact the way medications are metabolized through this enzyme.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More